Alector, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
ALEC$2.53+2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net Income (loss) | $78,680 | $(105,662) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation and amortization | 3,111 | 4,550 |
| Stock-based compensation | 7,514 | 21,815 |
| Amortization of premiums and accretion of discounts on marketable securities | (1,409) | (5,333) |
| Amortization of right-of-use assets | 3,005 | 2,852 |
| Amortization of debt discount and debt issuance costs | 177 | 215 |
| Impairment of right-of-use assets and leasehold improvements | — | 1,151 |
| Loss on extinguishment of debt | 603 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 3,779 | 2,143 |
| Other assets | 47 | 73 |
| Accounts payable | (551) | 2,542 |
| Accrued liabilities and accrued clinical supply costs | (14,302) | (13,993) |
| Payable to collaboration partner | (15,970) | 4,874 |
| Deferred revenue | (167,232) | (14,808) |
| License fee payable | 15,000 | — |
| Refund liability to collaboration partner | (15,438) | (38,104) |
| Lease liabilities | (5,544) | (4,865) |
| Other long-term liabilities | 346 | 210 |
| Net cash used in operating activities | (108,184) | (142,340) |
| Cash flows from investing activities: | ||
| Sale of property and equipment | 300 | — |
| Purchase of property and equipment | (149) | (41) |
| Purchase of marketable securities | (85,409) | (190,831) |
| Maturities of marketable securities | 213,417 | 358,890 |
| Sale of marketable securities | — | 2,981 |
| Net cash provided by investing activities | 128,159 | 170,999 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | — | 14,701 |
| Proceeds from the exercise of options to purchase common stock | 76 | — |
| Purchase of common stock under employee stock purchase plan | 48 | 122 |
| Repayment of debt financing | (10,429) | — |
| Net cash (used in) provided by financing activities | (10,305) | 14,823 |
| Net increase in cash, cash equivalents, and restricted cash | 9,670 | 43,482 |
| Cash, cash equivalents, and restricted cash at beginning of period | 67,648 | 34,867 |
| Cash, cash equivalents, and restricted cash at end of period | $77,318 | $78,349 |
| Supplemental Disclosures: | ||
| Cash paid for interest | $489 | $218 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.